Literature DB >> 26587323

Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment.

Monica Parodi1, Marco Pedrazzi1, Claudia Cantoni2, Monica Averna3, Mauro Patrone4, Maria Cavaletto4, Stefano Spertino4, Daniela Pende5, Mirna Balsamo1, Gabriella Pietra6, Simona Sivori3, Simona Carlomagno1, Maria Cristina Mingari7, Lorenzo Moretta8, Bianca Sparatore3, Massimo Vitale5.   

Abstract

In this study we characterize a new mechanism by which Natural Killer (NK) cells may amplify their recruitment to tumors. We show that NK cells, upon interaction with melanoma cells, can release a chemotactic form of High Mobility Group Box-1 (HMGB1) protein capable of attracting additional activated NK cells. We first demonstrate that the engagement of different activating NK cell receptors, including those mainly involved in tumor cell recognition can induce the active release of HMGB1. Then we show that during NK-mediated tumor cell killing two HMGB1 forms are released, each displaying a specific electrophoretic mobility possibly corresponding to a different redox status. By the comparison of normal and perforin-defective NK cells (which are unable to kill target cells) we demonstrate that, in NK/melanoma cell co-cultures, NK cells specifically release an HMGB1 form that acts as chemoattractant, while dying tumor cells passively release a non-chemotactic HMGB1. Finally, we show that Receptor for Advanced Glycation End products is expressed by NK cells and mediates HMGB1-induced NK cell chemotaxis. Proteomic analysis of NK cells exposed to recombinant HMGB1 revealed that this molecule, besides inducing immediate chemotaxis, also promotes changes in the expression of proteins involved in the regulation of the cytoskeletal network. Importantly, these modifications could be associated with an increased motility of NK cells. Thus, our findings allow the definition of a previously unidentified mechanism used by NK cells to amplify their response to tumors, and provide additional clues for the emerging role of HMGB1 in immunomodulation and tumor immunity.

Entities:  

Keywords:  HMGB1; NK cells; chemotaxis; melanoma cells; tumor microenvironment

Year:  2015        PMID: 26587323      PMCID: PMC4635845          DOI: 10.1080/2162402X.2015.1052353

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  67 in total

1.  Antisense oligonucleotide to cofilin enhances respiratory burst and phagocytosis in opsonized zymosan-stimulated mouse macrophage J774.1 cells.

Authors:  Reiko Adachi; Kosei Takeuchi; Kazuhiro Suzuki
Journal:  J Biol Chem       Date:  2002-09-23       Impact factor: 5.157

2.  Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1).

Authors:  Huan Yang; Peter Lundbäck; Lars Ottosson; Helena Erlandsson-Harris; Emilie Venereau; Marco E Bianchi; Yousef Al-Abed; Ulf Andersson; Kevin J Tracey; Daniel J Antoine
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

3.  NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1.

Authors:  Claudia Semino; Giovanna Angelini; Alessandro Poggi; Anna Rubartelli
Journal:  Blood       Date:  2005-03-31       Impact factor: 22.113

Review 4.  eIF5A isoforms and cancer: two brothers for two functions?

Authors:  M Caraglia; M H Park; E C Wolff; M Marra; A Abbruzzese
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

5.  The extracellular release of HMGB1 during apoptotic cell death.

Authors:  Charles W Bell; Weiwen Jiang; Charles F Reich; David S Pisetsky
Journal:  Am J Physiol Cell Physiol       Date:  2006-07-19       Impact factor: 4.249

Review 6.  HMGB1 and RAGE in inflammation and cancer.

Authors:  Gary P Sims; Daniel C Rowe; Svend T Rietdijk; Ronald Herbst; Anthony J Coyle
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

7.  DNA damage triggers nucleotide excision repair-dependent monoubiquitylation of histone H2A.

Authors:  Steven Bergink; Florian A Salomons; Deborah Hoogstraten; Tom A M Groothuis; Harm de Waard; Junxin Wu; Li Yuan; Elisabetta Citterio; Adriaan B Houtsmuller; Jacques Neefjes; Jan H J Hoeijmakers; Wim Vermeulen; Nico P Dantuma
Journal:  Genes Dev       Date:  2006-05-15       Impact factor: 11.361

8.  Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines.

Authors:  Niels Halama; Monika Braun; Christoph Kahlert; Anna Spille; Christian Quack; Nuh Rahbari; Moritz Koch; Jürgen Weitz; Matthias Kloor; Inka Zoernig; Peter Schirmacher; Karsten Brand; Niels Grabe; Christine S Falk
Journal:  Clin Cancer Res       Date:  2011-02-15       Impact factor: 12.531

9.  Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination.

Authors:  Uwe Zimmermann; Stefan Balabanov; Jürgen Giebel; Steffen Teller; Heike Junker; Dieter Schmoll; Chris Protzel; Christian Scharf; Britta Kleist; Reinhard Walther
Journal:  Cancer Lett       Date:  2004-06-08       Impact factor: 8.679

10.  Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair.

Authors:  Anthony Bouter; Céline Gounou; Rémi Bérat; Sisareuth Tan; Bernard Gallois; Thierry Granier; Béatrice Langlois d'Estaintot; Ernst Pöschl; Bent Brachvogel; Alain R Brisson
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

View more
  18 in total

Review 1.  Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.

Authors:  Sherman S Leung; Josephine M Forbes; Danielle J Borg
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

2.  Profile of differentially expressed Toll-like receptor signaling genes in the natural killer cells of patients with Sézary syndrome.

Authors:  Kelly C G ManfrereC; Marina P Torrealba; Denis R Miyashiro; Nátalli Z Pereira; Fabio S Y Yoshikawa; Luana de M Oliveira; Jade Cury-Martins; Alberto J S Duarte; José A Sanches; Maria N Sato
Journal:  Oncotarget       Date:  2017-09-18

3.  U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.

Authors:  Koji Haratani; Kimio Yonesaka; Shiki Takamura; Osamu Maenishi; Ryoji Kato; Naoki Takegawa; Hisato Kawakami; Kaoru Tanaka; Hidetoshi Hayashi; Masayuki Takeda; Naoyuki Maeda; Takashi Kagari; Kenji Hirotani; Junji Tsurutani; Kazuto Nishio; Katsumi Doi; Masaaki Miyazawa; Kazuhiko Nakagawa
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 4.  Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Authors:  Aura Muntasell; Mariona Cabo; Sonia Servitja; Ignasi Tusquets; María Martínez-García; Ana Rovira; Federico Rojo; Joan Albanell; Miguel López-Botet
Journal:  Front Immunol       Date:  2017-11-13       Impact factor: 7.561

5.  HMGB1 induces lung fibroblast to myofibroblast differentiation through NF‑κB‑mediated TGF‑β1 release.

Authors:  Qiong Wang; Jun Wang; Junfang Wang; Shanchao Hong; Feifei Han; Jingyu Chen; Guoqian Chen
Journal:  Mol Med Rep       Date:  2017-03-23       Impact factor: 2.952

6.  Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors.

Authors:  Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncotarget       Date:  2017-01-24

Review 7.  NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?

Authors:  Claudia Cantoni; Leticia Huergo-Zapico; Monica Parodi; Marco Pedrazzi; Maria Cristina Mingari; Alessandro Moretta; Bianca Sparatore; Segundo Gonzalez; Daniel Olive; Cristina Bottino; Roberta Castriconi; Massimo Vitale
Journal:  J Immunol Res       Date:  2016-05-12       Impact factor: 4.818

Review 8.  Redox control of cancer cell destruction.

Authors:  Csaba Hegedűs; Katalin Kovács; Zsuzsanna Polgár; Zsolt Regdon; Éva Szabó; Agnieszka Robaszkiewicz; Henry Jay Forman; Anna Martner; László Virág
Journal:  Redox Biol       Date:  2018-02-03       Impact factor: 11.799

Review 9.  Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.

Authors:  Alessandra Zingoni; Cinzia Fionda; Cristiana Borrelli; Marco Cippitelli; Angela Santoni; Alessandra Soriani
Journal:  Front Immunol       Date:  2017-09-25       Impact factor: 7.561

10.  Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration.

Authors:  Monica Parodi; Federica Raggi; Davide Cangelosi; Claudia Manzini; Mirna Balsamo; Fabiola Blengio; Alessandra Eva; Luigi Varesio; Gabriella Pietra; Lorenzo Moretta; Maria Cristina Mingari; Massimo Vitale; Maria Carla Bosco
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.